Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

The Journal of Clinical Investigation
Y WangJ M Egan

Abstract

Wistar rats develop glucose intolerance and have a diminished insulin response to glucose with age. The aim of this study was to investigate if these changes were reversible with glucagon-like peptide-1 (GLP-1), a peptide that we have previously shown could increase insulin mRNA and total insulin content in insulinoma cells. We infused 1.5 pmol/ kg-1.min-1 GLP-1 subcutaneously using ALZET microosmotic pumps into 22-mo-old Wistar rats for 48 h. Rat infused with either GLP-1 or saline were then subjected to an intraperitoneal glucose (1 g/kg body weight) tolerance test, 2 h after removing the pump. 15 min after the intraperitoneal glucose, GLP-1-treated animals had lower plasma glucose levels (9.04+/-0.92 mmol/liter, P < 0.01) than saline-treated animals (11.61+/-0.23 mmol/liter). At 30 min the plasma glucose was still lower in the GLP-1-treated animals (8.61+/-0.39 mmol/liter, P < 0.05) than saline-treated animals (10.36+/-0.43 mmol/liter). This decrease in glucose levels was reflected in the higher insulin levels attained in the GLP-1-treated animals (936+/-163 pmol/liter vs. 395+/-51 pmol/liter, GLP-1 vs. saline, respectively, P < 0.01), detected 15 min after glucose injection. GLP-1 treatment also increased pancreatic insulin...Continue Reading

References

Mar 1, 1992·Endocrinology·O NadivY Zick
Feb 11, 1991·Proceedings of the Society for Experimental Biology and Medicine·J M EganW S Evans
Sep 1, 1990·Diabetes Care·J L Leahy
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D J DruckerJ F Habener
Jun 4, 1974·Biochemistry·V GlisinC Byus
Jan 1, 1995·The Journal of Clinical Investigation·Z WangS R Bloom
Sep 1, 1996·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·R PerfettiJ M Egan

❮ Previous
Next ❯

Citations

Sep 29, 2005·Current Diabetes Reports·David A D'Alessio, Torsten P Vahl
Jul 7, 2012·Current Diabetes Reports·Claire M Issa, Sami T Azar
Nov 20, 2002·Biochemical and Biophysical Research Communications·Susan C Campbell, Wendy M Macfarlane
Nov 26, 1998·Progress in Lipid Research·C E BarryY Yuan
Jul 23, 2003·Trends in Pharmacological Sciences·TracyAnn Perry, Nigel H Greig
Jan 4, 2007·The Journal of Clinical Investigation·Daniel J Drucker
Apr 2, 2009·The Journal of Clinical Endocrinology and Metabolism·Rania Abu-HamdahDariush Elahi
Sep 22, 2010·PloS One·Qinghua WangGerald J Prud'homme
Mar 29, 2014·Expert Reviews in Molecular Medicine·Mukerrem Hale TasyurekSalih Sanlioglu
May 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Stacey L ConarelloBei B Zhang
Oct 4, 2013·Expert Opinion on Pharmacotherapy·Thomas Forst, Andreas Pfützner
Jan 9, 2003·Expert Opinion on Investigational Drugs·Daniel J Drucker
Jul 5, 2005·Expert Opinion on Investigational Drugs·J J Holst
Aug 9, 2012·Expert Opinion on Drug Metabolism & Toxicology·Teresa C DelgadoJohn G Jones
Jan 3, 2016·Molecular and Cellular Endocrinology·Isabel González-MariscalJosephine M Egan
Jan 18, 2011·Neurobiology of Learning and Memory·Alexis M Stranahan, Mark P Mattson
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Feb 18, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Nigel H GreigChaim G Pick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.